Completing data — refresh the page later to see the latest
68630-75-1CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1PYMDEDHDQYLBRT-DRIHCAFSSA-NBuserelin acetate is an organic molecular entity.
68630-75-1DTXSID30218712CHEMBL2106198CHEBI:31324Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
DescriptionBuserelin acetate is a potent analog of the hypothalamic hormone, luteinizing hormone-releasing hormone (LH-RH). Chronic administration of higher doses of buserelin desensitizes the pituitary, resulting in a decreased production of luteinizing hormone (LH), follicle stimulating hormone (FSH), and eventually sex steroids (testosterone in males and estradiol in females). Initial approval is for use in achieving medical castration in the treatment of advanced prostate cancer. It has also been investigated for the treatment of endometriosis, leiomyoma, precocious puberty, advanced breast cancer and infertility.
UsesGondadotropin-releasing hormone agonist, used to treat hormone-responsive cancers such as prostate and breast cancer. Synthetic nonapeptide agonist analog of LH-RH. Antineolpastic (hormonal).
DefinitionChEBI: Buserelin acetate is an organic molecular entity.